Tag: GlobeNewswire

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

The stock options have an exercise price of $8.91 per share, which is equal to the closing price of the company’s common stock on October 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following the applicable employee’s commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to such employee’s continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreements covering the grants and were made as an inducement material to the applicable employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

The stock options have an exercise price of $8.91 per share, which is equal to the closing price of the company’s common stock on October 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following the applicable employee’s commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to such employee’s continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreements covering the grants and were made as an inducement material to the applicable employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

The stock options have an exercise price of $8.91 per share, which is equal to the closing price of the company’s common stock on October 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following the applicable employee’s commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to such employee’s continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreements covering the grants and were made as an inducement material to the applicable employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business

FORT MILL, S.C., Oct. 02, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (the “Company”), today announced its Board of Directors has approved changing its name and ticker symbol to Flyte Aviation, Inc. and “VJET,” respectively.

Additionally, the Company will effect a one-for-ten reverse stock split — as had been approved by stockholders at a Special Meeting of Stockholders April 15, 2026.   Every ten shares of common stock will be combined into one share, reducing the outstanding shares from approximately 21.0 million to approximately 2.1 million, with no change to the par value or authorized shares. The reverse stock split will not alter any stockholder’s percentage ownership interest, except for the treatment of fractional shares, and proportionate adjustments will be made to outstanding options, warrants and convertible preferred stock. Shares will begin trading with the new name and ticker, on a split-adjusted basis, effective at the opening of trading on Monday, October 5, 2026.The Company’s common stock remains listed on the NYSE American stock exchange and its new CUSIP number following the reverse stock split will be 74933X 807.

The name change highlights the Company’s growth trajectory as a leading private, regional jet aviation business.

Stockholders do not need to take any action. Whether the stockholders hold the Company’s common stock in physical certificate form, or at the transfer agent in book entry form, or at a broker dealer — all shares will be automatically adjusted – the Company’s exchange agent will seamlessly adjust the shares accordingly at no cost to the stockholders. No fractional shares will be issued; stockholders who would otherwise be entitled to a fractional share will instead be entitled to receive their pro rata portion of the net proceeds from the aggregation and sale of such fractional shares by the Company’s exchange agent.

About Flyte Aviation, Inc.

Catheter Precision, Inc. (to be renamed Flyte Aviation, Inc. effective October 5, 2026), through its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the US and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the expected timing and effects of the name change, ticker symbol change and reverse stock split, expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially, including the risk that the reverse stock split may not have the intended effect on the market price or liquidity of the Company’s common stock. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Investor Contact
IR@CatheterPrecision.com

Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business

FORT MILL, S.C., Oct. 02, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (the “Company”), today announced its Board of Directors has approved changing its name and ticker symbol to Flyte Aviation, Inc. and “VJET,” respectively.

Additionally, the Company will effect a one-for-ten reverse stock split — as had been approved by stockholders at a Special Meeting of Stockholders April 15, 2026.   Every ten shares of common stock will be combined into one share, reducing the outstanding shares from approximately 21.0 million to approximately 2.1 million, with no change to the par value or authorized shares. The reverse stock split will not alter any stockholder’s percentage ownership interest, except for the treatment of fractional shares, and proportionate adjustments will be made to outstanding options, warrants and convertible preferred stock. Shares will begin trading with the new name and ticker, on a split-adjusted basis, effective at the opening of trading on Monday, October 5, 2026.The Company’s common stock remains listed on the NYSE American stock exchange and its new CUSIP number following the reverse stock split will be 74933X 807.

The name change highlights the Company’s growth trajectory as a leading private, regional jet aviation business.

Stockholders do not need to take any action. Whether the stockholders hold the Company’s common stock in physical certificate form, or at the transfer agent in book entry form, or at a broker dealer — all shares will be automatically adjusted – the Company’s exchange agent will seamlessly adjust the shares accordingly at no cost to the stockholders. No fractional shares will be issued; stockholders who would otherwise be entitled to a fractional share will instead be entitled to receive their pro rata portion of the net proceeds from the aggregation and sale of such fractional shares by the Company’s exchange agent.

About Flyte Aviation, Inc.

Catheter Precision, Inc. (to be renamed Flyte Aviation, Inc. effective October 5, 2026), through its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the US and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the expected timing and effects of the name change, ticker symbol change and reverse stock split, expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially, including the risk that the reverse stock split may not have the intended effect on the market price or liquidity of the Company’s common stock. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Investor Contact
IR@CatheterPrecision.com

Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business

FORT MILL, S.C., Oct. 02, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) (the “Company”), today announced its Board of Directors has approved changing its name and ticker symbol to Flyte Aviation, Inc. and “VJET,” respectively.

Additionally, the Company will effect a one-for-ten reverse stock split — as had been approved by stockholders at a Special Meeting of Stockholders April 15, 2026.   Every ten shares of common stock will be combined into one share, reducing the outstanding shares from approximately 21.0 million to approximately 2.1 million, with no change to the par value or authorized shares. The reverse stock split will not alter any stockholder’s percentage ownership interest, except for the treatment of fractional shares, and proportionate adjustments will be made to outstanding options, warrants and convertible preferred stock. Shares will begin trading with the new name and ticker, on a split-adjusted basis, effective at the opening of trading on Monday, October 5, 2026.The Company’s common stock remains listed on the NYSE American stock exchange and its new CUSIP number following the reverse stock split will be 74933X 807.

The name change highlights the Company’s growth trajectory as a leading private, regional jet aviation business.

Stockholders do not need to take any action. Whether the stockholders hold the Company’s common stock in physical certificate form, or at the transfer agent in book entry form, or at a broker dealer — all shares will be automatically adjusted – the Company’s exchange agent will seamlessly adjust the shares accordingly at no cost to the stockholders. No fractional shares will be issued; stockholders who would otherwise be entitled to a fractional share will instead be entitled to receive their pro rata portion of the net proceeds from the aggregation and sale of such fractional shares by the Company’s exchange agent.

About Flyte Aviation, Inc.

Catheter Precision, Inc. (to be renamed Flyte Aviation, Inc. effective October 5, 2026), through its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the US and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the expected timing and effects of the name change, ticker symbol change and reverse stock split, expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially, including the risk that the reverse stock split may not have the intended effect on the market price or liquidity of the Company’s common stock. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Investor Contact
IR@CatheterPrecision.com

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Oral Presentation Details:

Title:	Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN trial
Authors:	Liffert Vogt, MD, PhD, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam; Patrick J. Heagerty, PhD, Professor of Biostatistics at University of Washington; Sarbani Bhaduri, MD, MS, Vice President of Clinical Research at Mineralys Therapeutics, Inc.

About Launch-HTN 

The Launch-HTN trial (NCT06153693) was a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily with the option to increase to 100 mg at week six based on prespecified criteria; or placebo. The primary endpoint was change from baseline in systolic blood pressure at six weeks versus placebo, measured by automated office blood pressure monitoring.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their blood pressure goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Chronic Kidney Disease (CKD)

CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 1 in 10 (14%) adults aged 18 or older (approximately 37 million people) are estimated to have CKD. Approximately 21% of adults with high blood pressure are estimated to have CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to both uncontrolled blood pressure and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the Food and Drug Administration’s (FDA) review of Mineralys’ accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com